Aurobindo Pharma Ltd., headquartered in India, has received FDA approval to market the 300mg strength of its Cefdinir capsules in the US. Cefdinir is a generic version of Abbott Laboratories’ Omnicef, which is used to treat or prevent bacterial infections. According to IMS Health, Omnicef sales totaled about $787 million in 2006. Aurobindo Pharma already has FDA approval to market the 125mg and 250mg strengths of Cefdinir capsules.